Tempus AI has partnered with United Therapeutics to develop medical device software that uses AI to detect early-stage pulmonary hypertension (PH).
The partnership expects to study the use of AI to identify individuals at risk of undiagnosed PH via analysis of electrocardiogram results. Tempus' AI-powered care pathway intelligence solution, Tempus Next, will be used in the deployment process for a prospective clinical study, conducted among 60 selected centers. During the study, clinicians will evaluate the product’s ability to detect patients at risk of undiagnosed PH and track clinical outcomes of patients identified for further evaluation. The study aims to provide novel solutions to expedite diagnosis and enhance patient outcomes.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.